Finance

Lists
Q2 2026 earnings • released • EPS beat +159.28% • Revenue beat +85.70%
See results
22Z:ETR
Zealand Pharma A/S
€43.09
+0.44%
(+0.19) 1D
Aug 14, 5:30:00 PM GMT+2  ·   EUR
All symbols
SymbolPriceChange% Change
Generating top insights for 22Z...
Open
€44.42
High
€44.75
Low
€43.09
Mkt. cap
24.42B
Avg. vol.
322.00
Volume
1.04K
52-wk high
€73.90
52-wk low
€31.45
No. of employees
578
Open
€44.42
High
€44.75
Low
€43.09
Mkt. cap
24.42B
Avg. vol.
322.00
Volume
1.04K
52-wk high
€73.90
52-wk low
€31.45
No. of employees
578
News stories
From web sources and news partners
Profile
Zealand Pharma A/S is a Danish biotechnology research company, which designs and develops peptide-based medicines, mainly focusing on metabolic diseases like diabetes and obesity. The company's head office is situated in Søborg near Copenhagen, and it has close to 200 employees. In 2018, they opened a subsidiary in the US. Zealand Pharma forms part of the Danish-Swedish life science cluster Medicon Valley. Wikipedia
About Zealand Pharma A/S
CEOAdam Steensberg
Employees578
FoundedApr 1, 1997
Headquarters-
SectorBiotechnology
Websitezealandpharma.com
Last report
Aug 13, 2026
Fiscal period
Q2 2026
EPS / Est. (DKK)
DKK 55.34 / DKK 21.34
+159.28%beat
Revenue / Est. (DKK)
4.49B / 2.42B
+85.70%beat
Fiscal Q2 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in DKK
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in DKK
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
49.57M
68.92M
34.00M
4.49B
Cost of goods sold
-
-
-
-
Cost of revenue
-
-
-
-
Research and development expenses
320.04M
530.07M
469.00M
516.00M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
190.85M
91.81M
104.00M
116.00M
Operating expense
510.89M
621.88M
573.00M
632.00M
Total operating expenses
510.89M
621.88M
573.00M
632.00M
Operating income
-461.32M
-552.97M
-539.00M
3.86B
Other non operating income
-17.59M
-7.23M
24.00M
-91.00M
EBT including unusual items
-366.73M
-406.51M
-394.00M
4.01B
EBT excluding unusual items
-383.62M
-460.20M
-375.00M
3.97B
Income tax expense
37.50M
-27.39M
-
89.00M
Effective tax rate
-10.23%
6.74%
-
2.22%
Other operating expenses
-
1.00K
-
-
Net income
-404.23M
-379.12M
-394.00M
3.92B
Net profit margin
-815.50%
-550.12%
-1,158.82%
87.22%
Earnings per share
-5.75
-5.19
-5.58
55.34
Interest and investment income
108.95M
102.41M
74.00M
72.00M
Interest expense
-7.00M
-7.07M
-5.00M
-8.00M
Net interest expenses
101.95M
95.34M
69.00M
64.00M
Depreciation and amortization charges
-
-
-
-
EBITDA
-454.10M
-550.48M
-529.00M
3.87B
Gain or loss from assets sale
-
-
-
-
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps